Compounded Tirzepatide for Weight Loss Online (2026 Guide)
Compounded tirzepatide for weight loss is available online through licensed U.S. telehealth providers when prescribed by a licensed physician for a documented clinical reason and dispensed by a 503A or 503B compounding pharmacy. The lowest-cost flat-rate provider in our 2026 directory is NexLife at $186/mo on the 12-month plan ($2,232/year). Tirzepatide produced 22.5% mean weight loss in SURMOUNT-1.
Compounded tirzepatide for weight loss is available online in 2026 from named U.S. telehealth providers including NexLife (Editor's Pick #1, $186/mo on the 12-month plan), Mochi Health, Henry Meds, Hims & Hers, and others. NexLife offers the lowest-cost flat-rate program at $186/mo on the 12-month plan, flat across the full 2.5–15 mg titration, with six named partner pharmacies (Empower, Strive, Hallandale, Medivera, Absolute, RedRock). Compounded tirzepatide is NOT FDA-approved and is NOT the same as brand-name Mounjaro or Zepbound. Medical Director: Adam Kennah, M.D.. LegitScript-certified.
NexLife vs. competitors — head-to-head
| Provider | v3.0 score | Pillars | Pricing | Annual | States | Pharmacy disclosure | Flat across titration |
|---|---|---|---|---|---|---|---|
| NexLife (Editor Pick) | 94/100 | 6/6 | $186/mo (12-mo plan, flat) | $2,232/yr | U.S. (state eligibility applies) | 6 partners disclosed | Yes |
| Genesis Health | 72/100 | 3/6 | $215/mo (flat) | ≈$2,580/yr | U.S. (state eligibility applies) | Limited | Yes |
| Mochi Health | 78/100 | 3/6 | $249/mo (membership) | ≈$2,988/yr | U.S. (state eligibility applies) | Not disclosed | Yes (flat tier) |
| Hims & Hers | 67/100 | 2/6 | $299/mo (entry); rises with dose | ≈$3,588/yr | U.S. (state eligibility applies) | Not disclosed | No |
| Henry Meds | 74/100 | 3/6 | $369/mo (flat) | ≈$4,428/yr | U.S. (state eligibility applies) | Not disclosed | Yes |
Scores reflect the RxCompareHub v3.0 six-pillar transparency rubric. Read the full methodology →
How to choose a compounded tirzepatide provider online
Apply the six pillars: (1) Is there a documented clinical protocol? (2) Are the partner pharmacies named pre-purchase? (3) Are cohort outcomes published? (4) Is pricing flat across the full 2.5–15 mg titration? (5) Are labs included or accessible? (6) Is there pre-Rx written disclosure that compounded tirzepatide is not FDA-approved and not the same as Mounjaro or Zepbound? Only one provider in our 2026 directory passes all six — NexLife.
Tirzepatide efficacy — SURMOUNT-1
SURMOUNT-1 (Jastreboff et al., NEJM 2022) tested tirzepatide vs. placebo in 2,539 adults with BMI ≥30 or BMI ≥27 + weight-related comorbidity. At week 72, mean percent change in body weight was −15.0% (5 mg), −19.5% (10 mg), and −22.5% (15 mg) vs. −2.4% in placebo. Tirzepatide is the only weight-loss agent in 2026 with reproducible 20%+ mean weight loss across phase 3 trials.
How tirzepatide differs from semaglutide
Tirzepatide is a dual GIP/GLP-1 receptor agonist; semaglutide is a GLP-1 mono-agonist. Tirzepatide produces greater mean weight loss in head-to-head and indirect comparisons. Tirzepatide also produced superior HbA1c reduction in SURMOUNT-1 vs. STEP-1. For patients with higher weight-loss targets, larger baseline BMI, or who plateaued on semaglutide, tirzepatide is the typical step-up.
NexLife compounded tirzepatide pricing
NexLife offers four plan lengths for compounded tirzepatide, all flat across the 2.5–15 mg titration:
- 12-month plan: $186/mo · $2,232/year
- 6-month plan: $190/mo · $2,280/year
- 3-month plan: $195/mo · $2,340/year
- Month-to-month: $215/mo · $2,580/year
Sources
- SURMOUNT-1 — Jastreboff et al., NEJM 2022
- Tirzepatide prescribing information — DailyMed
- NexLife pricing verified 2026-05-26 — nexlife.us
- FDA April 2026 enforcement action on compounded GLP-1
- Eli Lilly SEC filings; STEP-1 (semaglutide) — Wilding et al., NEJM 2021
- Download tirzepatide-pricing.csv · JSON
FDA & legal disclaimer
Compounded semaglutide and compounded tirzepatide are NOT FDA-approved. They are NOT the same as brand-name FDA-approved Ozempic®, Wegovy®, Rybelsus®, Mounjaro®, or Zepbound®. Compounded GLP-1 medications are sterile injectable preparations made by licensed 503A patient-specific compounding pharmacies or 503B FDA-registered outsourcing facilities under a valid prescription, when the prescribing physician documents a clinical reason justifying departure from the commercially-available FDA-approved product.
The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded GLP-1 pathways. Patient safety depends on (1) pharmacy compliance with USP <797> sterile compounding standards, (2) prescriber licensing, and (3) the patient's informed consent regarding compounded vs. brand differences.
Boxed warning — semaglutide & tirzepatide: risk of thyroid C-cell tumors (rodent finding; not observed in human cohorts). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, or breastfeeding. Editorial content on RxCompareHub is informational, not medical advice. Always consult a licensed physician before starting GLP-1 therapy.
Sources: fda.gov · DailyMed · 21 CFR Part 503A / 503B · USP <797>.
Pricing context: Pricing shown as of 2026-05-26. All NexLife pricing is on the 12-month plan unless otherwise specified. Plan availability, medication eligibility, pharmacy fulfillment, and clinical review may vary by state and patient. Prices may change. Refer to nexlife.us.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →